Board member gets 4,678-share equity award at Elanco (NYSE: ELAN)

Rhea-AI Filing Summary

HOOVER R DAVID reported acquisition or exercise transactions in this Form 4 filing.

Elanco Animal Health Inc director R. David Hoover received a grant of 4,678 shares of Common Stock as deferred stock units, described as a pro-rated annual equity award for non-employee board members. The award carried a grant price of $0.00 per share, reflecting its compensation nature rather than a market purchase.

After this grant, Hoover directly holds 111,451 shares of Elanco common stock. He also has indirect holdings reported through the Suzanne A. Hoover Revocable Trust with 15,920 shares and another Revocable Trust with 150,000 shares, providing additional indirect exposure to Elanco shares.

Insider Trade Summary

Net Buyer: 4,678 shares

Net Buy 3 txns

Insider HOOVER R DAVID

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,678	$0.00	$0.00
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 111,451 shares (Direct); Common Stock — 150,000 shares (Indirect, Revocable Trust); Common Stock — 15,920 shares (Indirect, Suzanne A. Hoover Revocable Trust)

Footnotes (1)

1. F1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.

Key Figures

Deferred stock unit grant: 4,678 shares Grant price: $0.00 per share Direct holdings after grant: 111,451 shares +2 more

5 metrics

Deferred stock unit grant 4,678 shares Common Stock award to non-employee director

Grant price $0.00 per share Equity compensation award, not market purchase

Direct holdings after grant 111,451 shares R. David Hoover Common Stock position following award

Suzanne A. Hoover Revocable Trust holdings 15,920 shares Indirect Elanco Common Stock ownership

Other Revocable Trust holdings 150,000 shares Additional indirect Elanco Common Stock ownership

Key Terms

deferred stock units, pro-rated annual equity award, non-employee members of the Issuer's Board of Directors

3 terms

deferred stock units financial

"Grant of deferred stock units as a pro-rated annual equity award"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

pro-rated annual equity award financial

"as a pro-rated annual equity award to each of the non-employee members"

non-employee members of the Issuer's Board of Directors financial

"to each of the non-employee members of the Issuer's Board of Directors"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/26/2026 - 04:45 PM Learn about SEC filing dates

FAQ

What did Elanco (ELAN) director R. David Hoover report in this Form 4?

R. David Hoover reported receiving 4,678 Elanco Common Stock deferred stock units as a pro-rated annual equity award for non-employee board members. The grant was recorded at $0.00 per share and increased his directly held Elanco shares to 111,451.

How many Elanco (ELAN) shares were granted to the director in this filing?

The filing shows a grant of 4,678 shares of Elanco Common Stock as deferred stock units. This grant is described as a pro-rated annual equity award for non-employee members of the Board of Directors, and it did not involve a cash purchase price.

What are R. David Hoover’s direct Elanco (ELAN) share holdings after the grant?

After the reported grant, R. David Hoover directly holds 111,451 shares of Elanco Common Stock. This direct ownership figure reflects the impact of the 4,678-share deferred stock unit award described as a pro-rated annual equity grant to non-employee directors.

What indirect Elanco (ELAN) holdings are reported for trusts associated with Hoover?

The Form 4 lists 15,920 Elanco shares held indirectly through the Suzanne A. Hoover Revocable Trust and 150,000 shares held through another Revocable Trust. These indirect positions are separate from Hoover’s 111,451 directly held shares reported after the equity grant.

Was the Elanco (ELAN) director’s 4,678-share award a market purchase or compensation grant?

The 4,678 shares were issued as a compensation grant, not a market purchase. They are described as deferred stock units granted as a pro-rated annual equity award to non-employee board members, with a stated grant price of $0.00 per share in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOOVER R DAVID

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS INDIANA 46221

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		4,678(1)	A	$0	111,451	D
Common Stock								150,000	I	Revocable Trust
Common Stock								15,920	I	Suzanne A. Hoover Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.

	/s/ Amy C. Seidel, as Attorney-in-Fact for R. David Hoover	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)